What to do next · Intimacy & desire
Intimacy & desire: what to do next
What this often points to
This path covers two different things that often overlap: vaginal dryness or discomfort, and lower desire. They have different causes and different treatments.
Dryness and discomfort: genitourinary syndrome of menopause (GSM)
- GSM affects about 27% to 84% of postmenopausal women. The Menopause Society says it is "likely underdiagnosed and undertreated" 1.
- As estrogen falls at menopause, the Society says the vulva and vagina can become "thin, dry, and less elastic", with less lubrication. This can cause pain during intercourse and during pelvic exams, plus burning, itching or irritation 2.
- Many women don't notice GSM in perimenopause. For some it doesn't become a problem until several years after menopause 2. Unlike hot flashes, it tends to persist or progress.
Lower desire
- The Menopause Society says "there is no standard to meet when it comes to sexual activity and desire". Some women have less interest at midlife, some more, some no change 3.
- Hormone changes "are only part of a complex set of factors" 3. The others it names:
- poor sleep from night sweats
- pain from dryness
- medicines
- medical conditions
- relationship and life changes
- Clinicians call one recognized form of low desire hypoactive sexual desire disorder (HSDD). The Global Consensus says diagnosing it should be based on a thorough clinical assessment guided by available diagnostic criteria 4.
The hormone picture
- Estrogen and progesterone. ACOG says that from your 30s and 40s, the amount of estrogen the ovaries make "begins to fluctuate" 5. The Menopause Society says perimenopause brings "the ovaries' erratic production of hormones and less-frequent release of an egg (ovulation)" 2. The FDA says the body "slowly produces less of the hormones, estrogen and progesterone" 6.
- Testosterone. The ovaries make testosterone too 5. The Global Consensus, endorsed by The Menopause Society, says testosterone levels decline during the reproductive years 4. The Menopause Society notes that surgical removal of both ovaries causes "a significant decrease in testosterone that does not occur with natural menopause" 7.
Can a blood test settle it? Usually not, for either question.
- Perimenopause. ACOG says: "You probably don't need hormone testing." Your age, symptoms and period changes usually tell the story. Testing may be offered if you're under 45 with bleeding changes, especially under 40 8. NICE advises against hormone and ovarian tests to identify perimenopause at 45 or over 9.
- Low desire. "A blood total testosterone level should not be used to diagnose HSDD" 4. Diagnosis takes a full clinical assessment 4.
What to track for 2 weeks
- Dryness or discomfort day to day, 0–10. Note where: vulva, vagina, or with urination.
- Pain during intimacy, 0–10, and what helped (for example, a lubricant).
- Any bleeding after intercourse, or any bleeding at all if you're past menopause.
- Desire, 0–10. Separately: how much a change in desire bothers you, 0–10. The second number matters as much as the first.
- Urinary symptoms: urgency, frequency, burning, infections.
- Sleep, night sweats and mood.
- Medicines. Note any breast cancer history and treatment.
Questions to ask your clinician
- "Could this be genitourinary syndrome of menopause? Would an exam help confirm it?"
- "Should I start with an over-the-counter moisturizer or lubricant? When would we move to a prescription?"
- "Is low-dose vaginal estrogen an option for me, given my history? If I've had breast cancer, should we involve my oncologist?"
- "Could any of my medicines be lowering my desire?"
- "My lower desire bothers me. Does it meet the criteria for HSDD, and what are the options, including a referral to a clinician who specializes in sexual concerns?"
- "If testosterone comes up, what exact product would it be, is it FDA-approved for women, and how would you monitor it?"
The options on the table
These are the authorities' own grades and words. They aren't a ranking for you.
For dryness and discomfort (GSM)
- "effective and generally safe for the treatment of GSM, with minimal systemic absorption" (Level I)
- preferred over systemic therapy when estrogen is used only for genitourinary symptoms (Level I)
- improves sexual function in postmenopausal women with GSM (Level I)
- "progestogen therapy is not required" with it 17
In November 2025 the FDA moved to remove the boxed warning from low-dose vaginal estrogen. The Menopause Society agreed, calling it "a safe and effective therapy for a condition that affects most menopausal women" 10.
Want to hear a specialist talk this through? On the podcast unPAUSED, OB/GYN and Certified Menopause Practitioner Dr. Mary Claire Haver talks with Dr. Rachel Rubin, a board-certified urologist and sexual medicine specialist at Georgetown University, about vaginal dryness and discomfort, vaginal estrogen and DHEA, and pelvic floor therapy. It's a good listen if you've been told discomfort is just part of getting older: Menopause, Hormones and Women's Sexual Health with Dr. Rachel Rubin. Dr. Haver sells Pause-brand products on the same site, and we don't endorse them or use affiliate links.
For lower desire
- The one evidence-based use. "The only evidence-based indication for the use of testosterone in women is for the treatment of postmenopausal women who have been diagnosed as having HSDD after formal biopsychosocial assessment (Level I, Grade A)" 4.
- Effect size. In those women it adds, on average, about "one satisfying sexual event per month" above placebo (Level I, Grade A) 4. A 2019 meta-analysis of 36 trials found a similar effect 12.
- Before menopause. There are insufficient data for any recommendation in premenopausal women 4. Note: The Menopause Society's patient page says there's evidence it may help low desire in "both perimenopausal and postmenopausal women" 3. Ask your clinician which applies to you.
- No FDA-approved product for women. "There is no FDA-approved testosterone formulation for the management of menopausal symptoms" (ACOG) 13. The Global Consensus calls for testosterone products made for women 4.
- Forms the authorities advise against. Compounded "bioidentical" testosterone "cannot be recommended" unless no authorized equivalent is available 4. Pellets, injections, and anything giving above-normal levels are "not recommended" 4. ACOG recommends preparations other than pellets 13. Oral testosterone is not recommended because of its effects on cholesterol (Level I, Grade A) 4.
- Not for mood, thinking or wellbeing. Testosterone isn't shown to help depressed mood (Level I, Grade B), isn't supported for cognition, and showed no effect on general wellbeing (Level I, Grade A) 4.
- Side effects and unknowns. Mild increases in acne and body or facial hair in some women (Level I, Grade A). Long-term breast safety data are lacking 4.
What the research tested
Testosterone in postmenopausal women (meta-analysis, Lancet Diabetes & Endocrinology, 2019). 36 randomized trials, 8,480 participants 12.
- Compared with placebo or a comparator, testosterone increased the frequency of satisfying sexual events (mean difference 0.85, 95% CI 0.52–1.18). The Global Consensus summarizes the effect as about one more satisfying event a month 4.
- It also improved desire, arousal, orgasm and pleasure, and reduced sexual distress.
- Taken by mouth, it raised LDL ("bad") cholesterol. Non-oral forms such as patches or creams didn't.
- Acne and hair growth were more likely. No serious adverse events were recorded.
What it tested: mostly short trials in postmenopausal women. Limitation: the authors say long-term safety, and effects on wellbeing and cognition, still need study.
Limitation
Desire is personal, and the trials measure averages. A medicine that adds one satisfying event a month on average may matter a lot to one woman and not at all to another. Most trials are short and exclude women with breast cancer.
Supplements
"Libido" supplements are a big business, and the research behind them is thin. Here's what's actually been studied for desire and comfort, one ingredient at a time, plus two vaginal options that sit near the supplement aisle but have stronger evidence.
How we label evidence: Studied, some benefit means at least some randomized trials found a benefit, usually small or short. Mixed results means trials disagree. Little evidence means few studies, or no clear benefit over placebo. The labels describe the research. They are not recommendations, and the list is not a ranking.
The FDA doesn't approve supplements for safety before they're sold 14.
Maca
Little evidence
What the research found
In a crossover trial with 14 postmenopausal women, scores for intimacy-related problems on a menopause symptom scale improved during the 6 weeks on maca compared with placebo. Maca didn't change hormone levels 15. A systematic review of maca for menopause symptoms found only 4 small trials and called the evidence "limited." It also said safety hasn't been proven 16.
DHEA pills (oral supplements)
Little evidence
Safety: NCCIH says the long-term safety of DHEA supplements is unknown, and some evidence suggests even short-term use may be harmful, including liver damage 17.
What the research found
DHEA is a hormone the body turns into testosterone and estrogen. NCCIH says it's uncertain whether DHEA supplements help menopause symptoms 17.
Vaginal DHEA (prasterone): a prescription, not a supplement
See it in the options on this path ↑
What the research found
This is different from DHEA pills. Prasterone vaginal inserts (Intrarosa) are FDA-approved for "moderate to severe dyspareunia," meaning pain with intimacy, "a symptom of vulvar and vaginal atrophy, due to menopause" 18. The Menopause Society lists vaginal DHEA among treatments shown to work for genitourinary syndrome of menopause (GSM) 1. We cover it in the options on this path.
Vaginal moisturizers and lubricants
Studied, some benefit
See it in the options on this path ↑
What the research found
These aren't supplements, but they're sold next to them. The Menopause Society's 2020 GSM statement lists vaginal lubricants and moisturizers among options that "demonstrate effectiveness, depending on the severity of symptoms" 1. They're a common first step for dryness and discomfort.
Something to notice this week: On the 0–10 scale from this path, note discomfort during intimacy and whether a lubricant or moisturizer made a difference.
A question for your clinician: "Is what I'm feeling low desire, discomfort, or both? Which options have real evidence for that?"
The honest caveat: No supplement has good trial evidence for desire after menopause. The maca data come from very small studies.
Worth mentioning to your provider: any vaginal bleeding after menopause. The FDA notes it can be a sign of a medical problem, so it's worth checking 6.
Information for better conversations, not a diagnosis.
This is research with sources, not medical advice. Talk to your clinician about your situation.
Evidence-checked · sources listed
Talk to a menopause-trained provider
Sources (all rechecked 2026-10-15)
- The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020. PMID 32852449. https://pubmed.ncbi.nlm.nih.gov/32852449/
- The Menopause Society. Perimenopause (patient education; GSM section). https://menopause.org/patient-education/menopause-topics/perimenopause
- The Menopause Society. Sexual Health (patient education). https://menopause.org/patient-education/menopause-topics/sexual-health
- Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019. PMID 31498871. https://pubmed.ncbi.nlm.nih.gov/31498871/ (full text PMC6821450). Endorsed by The North American Menopause Society (now The Menopause Society), the Endocrine Society, the International Menopause Society and others.
- ACOG. The Menopause Years (FAQ047, last reviewed Dec 2025). https://www.acog.org/womens-health/faqs/the-menopause-years
- US FDA Office of Women's Health. Menopause. https://www.fda.gov/consumers/womens-health-topics/menopause
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022. PMID 35797481. https://pubmed.ncbi.nlm.nih.gov/35797481/
- ACOG. Do I need to have testing of my hormone levels during perimenopause? (Sept 2025). https://www.acog.org/womens-health/experts-and-stories/ask-acog/do-i-need-to-have-testing-of-my-hormone-levels-during-perimenopause
- NICE NG23, recs 1.3.4–1.3.5. https://www.nice.org.uk/guidance/ng23/chapter/Recommendations
- The Menopause Society. Comments on the FDA announcement on hormone therapy (Nov 2025). https://menopause.org/press-releases/the-menopause-society-comments-on-the-fda-announcement-on-hormone-therapy ; FDA: https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
- Intrarosa (prasterone) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=intrarosa
- Islam RM, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019. PMID 31353194. https://pubmed.ncbi.nlm.nih.gov/31353194/
- ACOG. Compounded Bioidentical Menopausal Hormone Therapy: Clinical Consensus No. 6. Obstet Gynecol. Nov 2023. PMID 37856860. https://pubmed.ncbi.nlm.nih.gov/37856860/ (quote verified from the full text via a public copy hosted by the Alabama Board of Medical Examiners: https://www.albme.gov/uploads/pdfs/Compounded_Bioidentical_Menopausal_Hormone_Therapy.pdf)
- US FDA. Questions and Answers on Dietary Supplements. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements
- Brooks NA, et al. Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content. Menopause. 2008. PMID 18784609. https://pubmed.ncbi.nlm.nih.gov/18784609/
- Lee MS, et al. Maca (Lepidium meyenii) for treatment of menopausal symptoms: a systematic review. Maturitas. 2011. PMID 21840656. https://pubmed.ncbi.nlm.nih.gov/21840656/
- NCCIH. Menopausal Symptoms: In Depth. https://www.nccih.nih.gov/health/menopausal-symptoms-in-depth
- US FDA. Intrarosa (prasterone) vaginal inserts prescribing information, 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208470s000lbl.pdf